CN101259131A - 用于细胞增殖性障碍的二氢吲哚酮与化疗剂的联合给药 - Google Patents

用于细胞增殖性障碍的二氢吲哚酮与化疗剂的联合给药 Download PDF

Info

Publication number
CN101259131A
CN101259131A CNA2008100814220A CN200810081422A CN101259131A CN 101259131 A CN101259131 A CN 101259131A CN A2008100814220 A CNA2008100814220 A CN A2008100814220A CN 200810081422 A CN200810081422 A CN 200810081422A CN 101259131 A CN101259131 A CN 101259131A
Authority
CN
China
Prior art keywords
chemical compound
group
dimethyl
pyrroles
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2008100814220A
Other languages
English (en)
Chinese (zh)
Inventor
T·艾布拉姆斯
L·默里
N·普赖尔
J·M·彻林顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sugen LLC
Original Assignee
Sugen LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen LLC filed Critical Sugen LLC
Publication of CN101259131A publication Critical patent/CN101259131A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA2008100814220A 2002-11-15 2003-11-14 用于细胞增殖性障碍的二氢吲哚酮与化疗剂的联合给药 Pending CN101259131A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42638602P 2002-11-15 2002-11-15
US60/426,386 2002-11-15

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNB200380103225XA Division CN100430060C (zh) 2002-11-15 2003-11-14 用于细胞增殖性障碍的二氢吲哚酮与化疗剂的联合的制药用途

Publications (1)

Publication Number Publication Date
CN101259131A true CN101259131A (zh) 2008-09-10

Family

ID=32326343

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2008100814220A Pending CN101259131A (zh) 2002-11-15 2003-11-14 用于细胞增殖性障碍的二氢吲哚酮与化疗剂的联合给药
CNB200380103225XA Expired - Fee Related CN100430060C (zh) 2002-11-15 2003-11-14 用于细胞增殖性障碍的二氢吲哚酮与化疗剂的联合的制药用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB200380103225XA Expired - Fee Related CN100430060C (zh) 2002-11-15 2003-11-14 用于细胞增殖性障碍的二氢吲哚酮与化疗剂的联合的制药用途

Country Status (22)

Country Link
US (1) US20040152759A1 (enExample)
EP (1) EP1562600A4 (enExample)
JP (1) JP2006508981A (enExample)
KR (1) KR20050086594A (enExample)
CN (2) CN101259131A (enExample)
AR (1) AR042042A1 (enExample)
AU (1) AU2003290943A1 (enExample)
BR (1) BR0315630A (enExample)
CA (1) CA2506308A1 (enExample)
CO (1) CO5700778A2 (enExample)
GT (1) GT200300245A (enExample)
MX (1) MXPA05005150A (enExample)
NL (1) NL1024779C2 (enExample)
NO (1) NO20052578L (enExample)
PA (1) PA8588601A1 (enExample)
PE (1) PE20040835A1 (enExample)
PL (1) PL376954A1 (enExample)
RU (1) RU2342140C2 (enExample)
TW (1) TW200418837A (enExample)
UY (1) UY28081A1 (enExample)
WO (1) WO2004045523A2 (enExample)
ZA (1) ZA200503841B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109311811A (zh) * 2016-06-09 2019-02-05 有机合成药品工业株式会社 4-（哌啶-4-基）吗啉的制备方法

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100600550B1 (ko) * 2000-10-20 2006-07-13 에자이 가부시키가이샤 질소 함유 방향환 유도체
JPWO2004080462A1 (ja) 2003-03-10 2006-06-08 エーザイ株式会社 ｃ−Ｋｉｔキナーゼ阻害剤
WO2005044788A1 (ja) 2003-11-11 2005-05-19 Eisai Co., Ltd. ウレア誘導体およびその製造方法
AU2005333515B2 (en) * 2004-07-09 2012-05-10 Arizona Board Of Regents, Acting On Behalf Of The University Of Arizona Wortmannin analogs and methods of using same in combination with chemotherapeutic agents
JP4834553B2 (ja) 2004-09-17 2011-12-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 医薬組成物
US20090117197A1 (en) * 2005-03-21 2009-05-07 Vicus Therapeutics Llc Compositions and methods for ameliorating cachexia
AU2006227880A1 (en) * 2005-03-23 2006-09-28 Pfizer Products Inc. Anti-CTLA4 antibody and indolinone combination therapy for treatment of cancer
WO2006120557A1 (en) * 2005-05-12 2006-11-16 Pfizer Inc. Anticancer combination therapy using sunitinib malate
BRPI0611506A2 (pt) * 2005-06-03 2010-09-14 Novartis Ag Combinação de compostos pirimidilaminobenzamida e imatinib para tratar ou prevenir doenças proliferativas
US20100105031A1 (en) * 2005-08-01 2010-04-29 Esai R & D Management Co., Ltd. Method for prediction of the efficacy of vascularization inhibitor
US9006240B2 (en) 2005-08-02 2015-04-14 Eisai R&D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
EP1938842A4 (en) * 2005-09-01 2013-01-09 Eisai R&D Man Co Ltd METHOD FOR PRODUCING A PHARMACEUTICAL COMPOSITION COMPRISING IMPROVED CRASHING CHARACTERISTICS
JP5238504B2 (ja) * 2005-09-15 2013-07-17 カウンシル・オブ・サイエンティフィック・アンド・インダストリアル・リサーチ イミダゾリル基で置換された新規なステロイド誘導体およびインダン−１−オン誘導体
WO2007034327A1 (en) * 2005-09-20 2007-03-29 Pfizer Products Inc. Dosage forms and methods of treatment using a tyrosine kinase inhibitor
US20090053236A1 (en) * 2005-11-07 2009-02-26 Eisai R & D Management Co., Ltd. USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR
EP1964837A4 (en) * 2005-11-22 2010-12-22 Eisai R&D Man Co Ltd Antitumor agent against multiple myeloma
RU2448708C3 (ru) * 2006-05-18 2017-09-28 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое средство против рака щитовидной железы
DE102006024834B4 (de) * 2006-05-24 2010-07-01 Schebo Biotech Ag Neue Indol-Pyrrol-Derivate und deren Verwendungen
JPWO2008001956A1 (ja) * 2006-06-29 2009-12-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 肝線維症治療剤
CN1899616A (zh) * 2006-07-20 2007-01-24 中国人民解放军军事医学科学院生物工程研究所 非受体酪氨酸激酶c－Abl特异性抑制剂的新用途
CN101511793B (zh) 2006-08-28 2011-08-03 卫材R&D管理有限公司 针对未分化型胃癌的抗肿瘤剂
EP2119707B1 (en) 2007-01-29 2015-01-14 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated-type of gastric cancer
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
WO2009060945A1 (ja) 2007-11-09 2009-05-14 Eisai R & D Management Co., Ltd. 血管新生阻害物質と抗腫瘍性白金錯体との併用
US7855204B2 (en) * 2008-01-22 2010-12-21 Concert Pharmaceuticals Inc. Derivatives of gefitinib
EP2248804A4 (en) * 2008-01-29 2014-09-10 Eisai R&D Man Co Ltd COMBINED USE OF AN ANGIOGENESIS INHIBITOR AND A TAXANE
US20110275689A1 (en) * 2008-07-02 2011-11-10 Generics [Uk] Limited Preparation of 3-Pyrrole Substituted 2-Indolinone Derivatives
US20100143295A1 (en) * 2008-12-05 2010-06-10 Auspex Pharmaceuticals, Inc. Quinazoline inhibitors of egfr tyrosine kinase
AU2011270165B2 (en) 2010-06-25 2015-12-24 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
JP6021805B2 (ja) 2011-04-18 2016-11-09 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
EP3444363B1 (en) 2011-06-03 2020-11-25 Eisai R&D Management Co., Ltd. Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
CN103127096B (zh) * 2011-12-02 2015-11-25 杨子娇 吡咯基取代的吲哚类化合物在治疗青光眼病的应用
WO2013152193A2 (en) * 2012-04-04 2013-10-10 Beth Israel Deaconess Medical Center, Inc. Methods of treating proliferative disorders with malate or derivatives thereof
JPWO2014098176A1 (ja) 2012-12-21 2017-01-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体のアモルファス及びその製造方法
CN105264380B (zh) 2013-05-14 2017-09-05 卫材R&D管理有限公司 用于预测和评价子宫内膜癌受试者对乐伐替尼化合物响应性的生物标志
SMT202200367T1 (it) 2014-08-28 2022-11-18 Eisai R&D Man Co Ltd Derivato di chinolina a elevata purezza e metodo per la produzione dello stesso
CA2976325C (en) 2015-02-25 2023-07-04 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
CN107801379B (zh) 2015-06-16 2021-05-25 卫材R&D管理有限公司 抗癌剂
AU2016309356B2 (en) 2015-08-20 2021-06-24 Eisai R&D Management Co., Ltd. Tumor therapeutic agent
ES2971448T3 (es) 2017-02-08 2024-06-05 Eisai R&D Man Co Ltd Composición farmacéutica para el tratamiento de tumores
CA3061888A1 (en) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
KR20220072851A (ko) * 2019-09-26 2022-06-02 스타파마 피티와이 리미티드 치료용 덴드리머

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK283413B6 (sk) * 1992-08-06 2003-07-01 Warner-Lambert Company 2-Tioindoly, 2-indolíntióny a polysulfidy, ich selénové analógy a farmaceutické prostriedky na ich báze
EP1082305A4 (en) * 1998-05-29 2001-09-26 Sugen Inc PYRROL SUBSTITUTED 2-INDOLINONE EFFECTIVE AS A PROTEIN KINASE INHIBITOR
AU1928501A (en) * 1999-11-24 2001-06-04 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
MXPA02006263A (es) * 1999-12-22 2004-02-26 Sugen Inc Metodos de modulacion de la funcion de la cinasa de tirosina c-kit de la proteina con compuestos de indolinona.
MXPA02008021A (es) * 2000-02-15 2004-04-05 Sugen Inc Indolinonas sustituidas con pirroles inhibidoras de proteinquinasas.
MY128449A (en) * 2000-05-24 2007-02-28 Sugen Inc Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
AR042586A1 (es) * 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
US6797725B2 (en) * 2001-04-09 2004-09-28 Sugen, Inc. Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109311811A (zh) * 2016-06-09 2019-02-05 有机合成药品工业株式会社 4-（哌啶-4-基）吗啉的制备方法
CN109311811B (zh) * 2016-06-09 2022-09-09 有机合成药品工业株式会社 4-(哌啶-4-基)吗啉的制备方法

Also Published As

Publication number Publication date
GT200300245A (es) 2004-06-23
EP1562600A4 (en) 2008-06-25
TW200418837A (en) 2004-10-01
WO2004045523A3 (en) 2004-09-30
BR0315630A (pt) 2005-08-23
MXPA05005150A (es) 2005-07-22
EP1562600A2 (en) 2005-08-17
NL1024779C2 (nl) 2004-11-09
CA2506308A1 (en) 2004-06-03
AR042042A1 (es) 2005-06-08
ZA200503841B (en) 2006-09-27
PA8588601A1 (es) 2004-05-21
CN1711089A (zh) 2005-12-21
RU2342140C2 (ru) 2008-12-27
NL1024779A1 (nl) 2004-05-18
UY28081A1 (es) 2004-06-30
PE20040835A1 (es) 2004-11-18
NO20052578L (no) 2005-05-27
WO2004045523A2 (en) 2004-06-03
PL376954A1 (pl) 2006-01-09
JP2006508981A (ja) 2006-03-16
CO5700778A2 (es) 2006-11-30
KR20050086594A (ko) 2005-08-30
CN100430060C (zh) 2008-11-05
RU2005118417A (ru) 2006-01-20
US20040152759A1 (en) 2004-08-05
AU2003290943A1 (en) 2004-06-15

Similar Documents

Publication Publication Date Title
CN100430060C (zh) 用于细胞增殖性障碍的二氢吲哚酮与化疗剂的联合的制药用途
JP6963146B1 (ja) 癌を治療するためのｋｒａｓ阻害剤の投与
JP7596441B2 (ja) （ｓ）－５－アミノ－３－（４－（（５－フルオロ－２－メトキシベンズアミド）メチル）フェニル）－１－（１，１，１－トリフルオロプロパン－２－イル）－１ｈ－ピラゾール－４－カルボキサミドの噴霧乾燥分散体および製剤
TWI680760B (zh) 治療黑色素瘤的藥物組合
KR20210005222A (ko) Rip1 억제 화합물 및 이를 제조하고 사용하는 방법
JP2025134924A (ja) がんを処置するために使用され得る尿素誘導体
KR20150023752A (ko) 암 및 자가면역 질환 치료에 유용한 가역적인 공유 피롤로- 또는 피라졸로피리미딘
ES2744198T3 (es) Formulaciones farmacéuticas, procesos, formas sólidas y procedimientos de uso relacionados con 1-etil-7-(2-metil-6-(1H-1,2,4-triazol-3-il)piridin-3-il)-3, 4 dihidropirazino[2,3-b]pirazin-2(1H)-ona
JP2016512831A (ja) 重水素化されたパルボシクリブ
JP2020526572A (ja) パルボシクリブ及び６−（２，４−ジクロロフェニル）−５−［４−［（３ｓ）−１−（３−フルオロプロピル）ピロリジン−３−イル］オキシフェニル］−８，９−ジヒドロ−７ｈ−ベンゾ［７］アヌレン−２−カルボン酸を含む組み合わせ並びに癌の処置のためのその使用
TW202320792A (zh) 包含ｆｇｆｒ抑制劑及ｋｒａｓ抑制劑之組合療法
CN118338905A (zh) Wee1激酶抑制剂在治疗癌症中的应用
US10821114B2 (en) Derivatives of cephalosporin for treating cancer
JP2014005265A (ja) ピラゾール置換アミノ−ヘテロアリール化合物の誘導体
JP2021534114A (ja) 併用療法
WO2014081816A1 (en) Fluoro-derivatives of pyrazole-substituted amino-heteroaryl compounds
HK1120406A (en) Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders
EP4479047A1 (en) Drug combinations and methods of treating ovarian cancer
CN118666846A (zh) 苯甲羰基吲哚类衍生物及其用途
CN118459485A (zh) 用于治疗具有egfr突变的癌症的氨基取代杂环
CN117586265A (zh) 含氮杂环类化合物、其制备方法及其在医药上的应用
CN121159504A (zh) Fgfr蛋白降解靶向嵌合体及其用途
CN118632696A (zh) 包含fgfr抑制剂和kras抑制剂的组合疗法
CN116444523A (zh) 作为smarca2抑制剂的化合物及其应用
JP2007507552A (ja) Ｉｇｆ１ｒ阻害剤が誘発する高血糖を治療する方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1120406

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20080910

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1120406

Country of ref document: HK